key: cord-0890632-xgmnliwh
authors: Vasquez, Charles R.; Gupta, Shruti; Miano, Todd A.; Roche, Meaghan; Hsu, Jesse; Yang, Wei; Holena, Daniel N.; Reilly, John P.; Schrauben, Sarah J.; Leaf, David E.; Shashaty, Michael G.S.
title: Identification of distinct clinical subphenotypes in critically ill patients with COVID-19
date: 2021-05-06
journal: Chest
DOI: 10.1016/j.chest.2021.04.062
sha: 14a61566a295777ff7bd7df836c0e36a3bd133ef
doc_id: 890632
cord_uid: xgmnliwh

Background Subphenotypes have been identified in patients with sepsis and acute respiratory distress syndrome (ARDS), and are associated with different outcomes and response to therapies. Research Question Can unique subphenotypes be identified among critically ill patients with coronavirus disease 2019 (COVID-19)? Study Design & Methods: Using data from a multicenter cohort study that enrolled critically ill patients with COVID-19 from 67 hospitals across the United States, we randomly divided centers into Discovery and Replication cohorts. We utilized latent class analysis independently in each cohort to identify subphenotypes based on clinical and laboratory variables. We then analyzed the associations of subphenotypes with 28-day mortality. Results Latent class analysis identified four subphenotypes (SP) with consistent characteristics across Discovery (45 centers, n=2,188) and Replication (22 centers, n=1,112) cohorts. SP1 was characterized by shock, acidemia, and multi-organ dysfunction, including acute kidney injury treated with renal replacement therapy. SP2 was characterized by high C-reactive protein, early need for mechanical ventilation, and the highest rate of ARDS. SP3 had the highest burden of chronic diseases, while SP4 had limited chronic disease burden and mild physiologic abnormalities. 28-day mortality in the Discovery cohort ranged from 20.6% (SP4) to 52.9% (SP1). Mortality across subphenotypes remained different after adjustment for demographics, comorbidities, organ dysfunction and illness severity, regional and hospital factors: compared with SP4, SP1 relative risk (RR) 1.67 (95% CI 1.36-2.03); SP2 RR 1.39 (1.17-1.65); SP3 RR 1.39 (1.15-1.67). Findings were similar in the Replication cohort. Interpretation We identified four subphenotypes of COVID-19 critical illness with distinct patterns of clinical and laboratory characteristics, comorbidity burden, and mortality.

1 4 chronic diseases, while SP4 had limited chronic disease burden and mild physiologic 69 abnormalities. 28-day mortality in the Discovery cohort ranged from 20.6% (SP4) to 52.9% 70 (SP1). Mortality across subphenotypes remained different after adjustment for demographics, 71 comorbidities, organ dysfunction and illness severity, regional and hospital factors: compared 72 with SP4, SP1 relative risk (RR) 1.67 (95% CI 1.36-2.03); SP2 RR 1.39 (1.17-1.65); SP3 RR Coronavirus disease 2019 , caused by the novel coronavirus SARS-CoV-2, results 114 in a broad spectrum of disease manifestations, ranging from mild self-limited illness to life-115 threatening organ dysfunction. 1 The presence of biologically distinct subgroups, or 116 subphenotypes, has been hypothesized in critically ill patients with based upon 117 reports of differences in lung compliance, thrombotic complications, and inflammatory 118 response. [2] [3] [4] [5] [6] [7] To date, however, there is limited empiric evidence identifying and characterizing 119 COVID-19 clinical subphenotypes. 120 121 In other heterogeneous syndromes, such as sepsis, the acute respiratory distress syndrome 122 (ARDS), and acute kidney injury (AKI), latent class analysis has been used to identify distinct 123 subphenotypes based on clinical and biochemical characteristics. 7-12 These subphenotypes have 124 been associated not only with clinical outcomes but also, in retrospective analyses of clinical 125 trials data, with response to trial therapies such as high positive end-expiratory pressure for 126 ARDS and vasopressin for AKI. 9,10 Furthermore, the subphenotype-defining characteristics in 127 these studies yielded important insights into the heterogeneity of disease pathophysiology. 128 Identifying subphenotypes in critically ill COVID-19 patients may have similar ability to 129 elucidate pathophysiology, predict outcomes, and guide treatment selection. 130 131 We hypothesized that latent, currently uncharacterized, clinically and physiologically distinct 132 subphenotypes exist within critically ill COVID-19 patients, and that they are associated with 133 differences in the risk of important clinical outcomes. We therefore aimed to identify and 134 replicate COVID-19 subphenotypes based on clinical and laboratory variables in a large, 135 J o u r n a l P r e -p r o o f 7 multicenter cohort of intensive care unit (ICU) patients. We then examined the associations of 136 subphenotypes with 28-day mortality and other clinically relevant outcomes. Subphenotypes were identified using latent class analysis (LCA). LCA is a group of statistical 157 methods that can be used to identify unobserved (latent) subphenotypes within a heterogeneous 158 J o u r n a l P r e -p r o o f 8 population by clustering on observed characteristics, such as laboratory variables. 11 We 159 randomly split enrolling centers into Discovery and Replication cohorts targeting a 2:1 overall 160 patient ratio between the cohorts (See e- Figure 1 in the online data supplement). 161 162 We used 25 acute clinical and laboratory variables, selected a priori, as endogenous, class-163 defining variables (e -Table 3 ). Outcomes, such as mortality were not used to define classes. We 164 used ICU day one values for all class-defining variables included in the models. After class assignment, we examined the distributions of class-defining variables, baseline 176 demographics, and clinical characteristics across the candidate subphenotypes using heatmaps. 177 Heatmaps were created using Microsoft Excel for Mac (version 16.38) . Baseline characteristics 178 across the two cohorts and across subphenotypes were compared using descriptive statistics. Table 2 ). The five-class model, however, showed a substantial increase in class 217 assignment uncertainty (7.2-11.1% across classes v. 0.7-2.3% for the four-class model) and 218 contained a relatively small class comprising 7.4% of patients. The four-class model had class 219 proportions between 11.2% and 39.7%, with high mean class probabilities (0.85-0.91 across four 220 classes, e- Figure 2 ). Investigator review of the four-class model suggested that differences in 221 characteristics by class were clinically interpretable (see below). We then repeated model 222 derivation steps in the Replication cohort. The four-class model again showed improved model five-class model did not converge. We therefore maintained four-class models for each cohort, 226 with classes labeled as COVID-19 subphenotypes (SP) 1-4.

Characteristics distinguishing COVID-19 subphenotypes 229 Patterns of class-defining variables and baseline characteristics across the four subphenotypes 230 are shown in Figure 1 (see e- Table 6 and e- Table 7 for non-standardized numeric data). Patterns Compared to the subphenotypes derived using latent class modelling, a limited variable model 268 containing fewer, commonly available laboratory and vital sign data, did not reliably predict 269 class assignment (e- Table 8 ). and SP3 had a significantly higher risk of mortality after adjustment for demographics, 276 comorbidities, organ dysfunction and illness severity, and regional and hospital factors (Table 3) . 277 Similarly, restricted mean survival times were all significantly shorter in SP1-SP3 compared to 278 SP4 (e- Table 9 ). Additional pairwise comparisons using adjusted models are shown in e- Table   279 10.

Association of COVID-19 subphenotypes with 14-day clinical outcomes 282 While the unadjusted rates of invasive mechanical ventilation and ARDS were highest in SP1 283 and SP2 in both cohorts (Table 4) , only SP2 showed an increased ARDS incidence after 284 adjustment (Discovery: aHR 1.63 (95% CI 1.49-1.78), Replication: aHR 1.53 (95% CI 1.35-285 1.75)) (e -Table 11 ). 18 SP1 and SP2 were significantly associated with a higher risk of 286 thrombosis, even after adjustment for known venous thromboembolism risk factors (e -Table   287 11). 20 288 289

The rates of AKI and AKI requiring renal replacement therapy were higher in SP1-SP3 290 compared to SP4 (Table 4 , e- Table 11 ). Secondary infections occurring after ICU admission 291 were common across all subphenotypes, but only patients in SP2 experienced secondary 292 infections at a significantly higher rate than those in SP4, after adjustment for age, coinfection Replication cohorts (e -Table 12) , with the greatest use in SP1 and SP2 patients compared to SP3 301 and SP4. Steroid use was associated with significantly increased mortality risk in SP2-SP4 in the 302 Discovery cohort, but not in the Replication cohorts (e- Table 13 ). Anti-IL6 therapy was used less 303 frequently than corticosteroids across all subpheontypes (e- Table 12 ). Receipt of anti-IL6 304 therapy was not associated mortality within any subphenotype, in both the Discovery and 305 Replication cohort (e -Table 13 ). Anti-microbial therapy was commonly used across all 306 subphenotypes on ICU Day 1 and was not associated with mortality risk within any 307 subphenotype, in both the Discovery and Replication cohort (e -Table 13 ). Notably, however, the COVID-19 subphenotypes were characterized by a more defined 333 relationship between chronic and acute conditions. SP1 patients, who had severe acute 334 physiologic changes, were also typified by the high burden of comorbidities and elevated initial 335 serum creatinine seen in SP3 patients; in contradistinction, the δ sepsis subphenotype was 336 defined more by shock, with notably fewer comorbidities and lower creatinine than the β 337 phenotype. In addition, the δ sepsis phenotype had the highest P a O 2 , whereas COVID-19 SP1 338 phenotype patients had a high proportion of hypoxemia and respiratory failure, second only to 339 SP2 in severity. These differences, as well as a substantially higher mortality in our cohort, could Our study has several notable strengths. First, latent class models were generated independently 388 in two patient populations totaling 3,300 patients at 67 centers across the United States. The 389 subphenotype similarities between Discovery and Replication cohorts, two randomly selected 390 sets of STOP-COVID centers, lend external validity to our findings. Further strengthening the 391 validity of the identified classes, we found consistent subphenotype associations with 392 demographics, medical comorbidities, and clinical outcomes, even though these were not used to 393 define classes. Furthermore, the similarities in the timing of disease onset relative to hospital and 394 ICU admission across subphenotypes, provide evidence that subphenotypes describe truly 395 separate classes, rather than the same disease at different time points. Ascertainment of similar 396 subphenotypes when analysis is limited to patients receiving mechanical ventilated on ICU day 1 397 also supports this conclusion. In addition, our study population was diverse, both geographically 398 and demographically, which increases the generalizability of our findings and suggests that our 399 subphenotype classifications may be applicable to other COVID-19 cohorts. Our study's large 400 sample size may have enhanced our ability to detect more clinically distinguishable 401 subphenotypes than in studies of ARDS and AKI, and the same number of classes as a study of 402 >20,000 sepsis patients. 8-10 403 404 There are several important limitations of our study. First, the STOP-COVID study from which 405 our data were drawn was an observational study-while data were collected manually and 406 systematically, they were limited by what was available in the medical record. Substantial An additional limitation was lack of data on circulating novel molecular markers, such as soluble 415 tumor necrosis factor receptor-1, interleukin-6, and interleukin-8, which have been described as 416 important class-defining variables in other critical illness latent class models. 9,10 As noted, 417 follow-up studies in cohorts with biospecimens will be key to associating clinical with molecular 418 subphenotypes. The true incidence of some clinical outcomes, such as ARDS, may differ from 419 the reported incidence due to misclassificationfor example we were unable to phenotype 420 ARDS using direct chest radiograph review and expert consensus. Similarly, our data lacked 421 detailed information of respiratory physiology, such as respiratory system compliance, or 422 quantitative radiographic information, including extent of lung consolidation. The absence of 423 detailed biomarker and physiologic variables, as well as substantial missingness of variables 424 such as ferritin and D-Dimer, likely contributed to the inability to predict class assignment using 425 fewer, more commonly available clinical variables. Our findings regarding subphenotype 426 association with such outcomes, however, were consistent with the associations we observed for 427 outcomes less likely to have been misclassified, including AKI and mortality. Associations of subphenotypes (SP) 1, 2, and 3 with mortality are shown as relative risks (95% confidence intervals) compared with the reference of subphenotype 4. Models adjusted for: age, sex, race and ethnicity, hypertension, diabetes, chronic obstructive pulmonary disease, end-stage kidney disease, active malignancy, chronic liver disease, illness severity and organ dysfunction on ICU day 1 (respiratory support and oxygenation, platelet count, altered mental status, and creatinine), hospital ICU bed capacity, and U.S. region. Body mass index, vasopressor support, and liver transaminases were missing in a non-trivial number of patients (11.6-33.4%, see Table 1 ). Models also adjusting for these variables in patients with non-missing data showed minimal change in relative risks compared with those reported above. 

Deciding on the Number of Classes in Latent 481

Class Analysis and Growth Mixture Modeling: A Monte Carlo Simulation Study

Testing the number of components in a normal mixture

An Alternative Approach for the Analysis of 486

Time-to-Event and Survival Outcomes in Pulmonary Medicine

A modified poisson regression approach to prospective studies with binary data

Acute Respiratory Distress Syndrome

Global epidemiology and outcomes of acute 493 kidney injury

Venous thrombosis. Nat Rev Dis Primers

Canon-Montanez W. Risk 497 factors for health care-associated infection in hospitalized adults: Systematic review and 498 meta-analysis

Epidemiology and risk profile of heart failure

Kibbelaar Cook County Health

Gautam Kings County Hospital Center

Data are shown as n (%). Within each cohort, differences across subphenotypes were compared using the chi-squared test.Abbreviations: ARDS, acute respiratory distress syndrome; AKI, acute kidney injury; RRT, renal replacement therapy; CHF, congestive heart failure